AzTrials
AzTrials

Acute Heart FailureECO/TORNCT02122640

Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department

An observational study of Acute Heart Failure, run by Comitato Etico di Area Vasta Sud Est at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

LUNG ULTRASOUND IN THE MANAGEMENT OF DISPNEIC PATIENTS IN EMERGENCY DEPARTMENT Introduction This is a prospective randomized trial realized in the Emergency Department of the University Hospital of Siena, Italy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Heart Failure
How many people
Not given
Where
1 siteItaly
Study dates
Sep 2012to Sep 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All the patients admitted to our Emergency Department from January 2011 to February 2013 with acute non-traumatic dyspnea. We included patients carried by ambulance and patients who came autonomously.

Who may be able to join

  • All the patients admitted to our Emergency Department from January 2011 to February 2013 with acute non-traumatic dyspnea. We included patients carried by ambulance and patients who came autonomously.

Who cannot join

  • Age <18 years
  • Post-traumatic dyspnea

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Azienda Ospedaliera Universitaria Senese

    Siena, Siena, 53100

Other trials in Italy

About this study

LUNG ULTRASOUND IN THE MANAGEMENT OF DISPNEIC PATIENTS IN EMERGENCY DEPARTMENT

Introduction

Read more

This is a prospective randomized trial realized in the Emergency Department of the University Hospital of Siena, Italy.

Dyspnea is one of the most common causes worldwide of admission to the Emergency Department (ED) and acute heart failure (AHF) is a major cause of serious morbidity and death in such population, above all in elderly patients. Incidence rate is significantly higher in men than in women, in Europe it increases with age from 1.4/1000 person-years in subjects aged 55-59 years to 47.4/1000 person-years in those aged 90 years or older. The age-adjusted prevalence of AHF in the United States averages 36 cases per 100,000 of the population and accounts for 10,000 deaths annually.

In clinical practice this symptomatology is usually investigated in the pre-hospital phase only with history and physical examination; in the ED blood gas analysis (BGA), laboratory tests and chest X-rays can be performed as primary exams. BNP and NT pro-BNP are now considered reliable biochemical markers to distinguish cardiogenic from pulmonary etiology, both for their diagnostic and prognostic value. On the other hand, these biomarkers are affected by a "grey zone" of uncertainty, they are not available in all hospitals and their dosage samples are expensive: thus we propose other tools to support the diagnostic process.

Read the detailed description

THE RATIONALE OF THE STUDY

It is widely reported in literature that ultrasound can identify the presence of interstitial and pulmonary alveolar syndrome by comet tail artifact with good sensitivity and specificity. This is an easy technique to perform and interpret, readily available and repeatable over time and executable bedside even in emergency situations. The execution of this investigative technique in the ED and also in a pre-hospital setting would provide additional and reliable information for patients with dyspnea, so favoring rapid identification of the etiology.

Accepting these observations, lung ultrasound (LUS) could have a central role in the evaluation of patients with shortness of breath in ED. Even the LUS in many studies has been considered useful for detecting pulmonary alterations, there are few data regarding its utilization in clinical practice and there is a lack of evidences concerning validated operative protocols. On this basis, it was decided to evaluate the employment of LUS in the ED with a structured and practical protocol.

ETHICAL ASPECTS

This study will be conducted according to Helsinki Declaration and i twill be approved by our Local Ethics Committee.

AIMS OF THE STUDY

The main aim of this study was to analyze if lung ultrasound (LUS) could be a useful tool for the early identification of heart failure in patients presenting to ED for dyspnea.

The secondary objective was to identify a protocol model for the management of acute dyspnea on the basis of lung ultrasound pattern when added to other validated diagnostic tools.

INCLUSIONS CRITERIA

All the patients admitted to our Emergency Department from January 2011 to February 2013 with acute non-traumatic dyspnea. We included patients carried by ambulance and patients who came autonomously.

EXCLUSIONS CRITERIA

Age <18 years

Post-traumatic dyspnea

METHODS

After triage, standardized diagnostic work-up included: 1) brief patient history (age, gender, symptoms, medical history); 2) Vital Parameters (Blood Pressure, Heart Rate, Arterial Oxygen Saturation, Respiratory Rate, Body Temperature); 3) 12 lead EKG; 4) Standard laboratory assessment (NT-proBNP - ECLIA, Roche Methodics®, Creatinine, BUN, C-Reactive Protein, Full Blood Count, Electrolytes); 5) Blood Gas Analysis. Data were collected and stored in a database.

An independent operator performed LUS right after the admission (unaware of patient history and vitals), then the attending physician acquired full medical history, Physical Examination (according to Boston Criteria for Heart Failure) and requested Chest X-Ray. Echocardiography was performed in order to validate heart failure diagnosis even if it was not considered in our protocol because not available 24h/day in our Emergency Department. All LUS operators were emergency physicians trained in LUS.

Lung Ultrasound We used Esaote MyLab30™ and MyLab70™ Ultrasound with Variable-Band Convex Array (3,5-5 MHz). Six transversal scans for each hemithorax (second and fourth intercostal space on the hemiclavear line, anterior axillar line, middle axillar line, see Figure 1). Basal scans of the lung were sampled in order to identify pleural effusions.

We chose this anterior approach for the difficulties related to a complete evaluation of the chest in case of severe dyspnea and non-collaborative patients.

B-lines are defined as vertical, hyperechogenic, reverberation artifacts that arise from the pleural line to the bottom of the screen and moving synchronously with lung sliding; a positive region is defined by the presence of three or more B-lines in a longitudinal plane between two ribs. Acute interstitial pulmonary syndrome was defined, according to the International Consensus Conference on LUS, as the presence of two or more positive regions in each hemithorax.

Diagnostic Outcome (Reference Standard) Since a uniform reference test is lacking for acute heart failure, we chose to use a consensus diagnosis as formal reference standard, in analogy with earlier studies and as recommended by recent diagnostic research guidelines. An independent panel of experts (made up of two cardiologists and one senior emergency physician) judged all the collected data for each patient to determine the final diagnosis.

The panel of experts assessed acute heart failure diagnosis following the criteria and approach outlined by the ESC Heart Failure Guidelines.

LENGHT OF THE STUDY

From January 2011 to February 2013

DATA COLLECTION

Data collection form included:

Personal data Medical hystory VItals signs; ECG; BGA; Medical Examination; Standard Blood Test plus NT pro-BNP; Chest X-ray; Echocardiography; Lung Ultrasound

STATISTICAL ANALYSIS

Edited to Prof. Cevenini.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic Outcome (Reference Standard)

    Since a uniform reference test is lacking for acute heart failure, we chose to use a consensus diagnosis as formal reference standard, in analogy with earlier studies and as recommended by recent diagnostic research guidelines. An independent panel of experts (made up of two cardiologists and one senior emergency physician) judged all the collected data for each patient to determine the final diagnosis.

    The panel of experts assessed acute heart failure diagnosis following the criteria and approach outlined by the ESC Heart Failure Guidelines.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2014 (estimated)
  2. Study startSep 2012
  3. Primary completionFeb 2013
  4. Study completionSep 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
IDs, dates and publications
ClinicalTrials.gov ID
NCT02122640
Sponsor's protocol ID
ECO/TOR
Acronym
ECO/TOR
Status last verified
Apr 2014
First submitted
23 Apr 2014
Last updated
24 Apr 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Heart Failure, run by Comitato Etico di Area Vasta Sud Est at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic Outcome (Reference Standard) (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in